Cognition, function, and caregiving time patterns in patients with mild-to-moderate Alzheimer disease: A 12-month analysis

Alzheimer Disease and Associated Disorders

Volumn 19, Issue 1, 2005, Pages 29-36

  Feldman, Howard H ^a   Van Baelen, Bart ^b   Kavanagh, Shane M ^c   Torfs, Koen E L ^d  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b SGS Medisearch International NV   (Belgium)

^c JANSSEN RESEARCH FOUNDATION   (Belgium)

^d JANSSEN CILAG GMBH   (Germany)

Author keywords

Activities of daily living; Alzheimer's Disease Assessment Scale cognitive subscale; Caregiver time; Disability assessment in dementia; Mini Mental State Examination; Sabeluzole

Indexed keywords

PLACEBO; SABELUZOLE;

AGED; ALZHEIMER DISEASE; ARTICLE; CAREGIVER; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DISABILITY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; MALE; MINI MENTAL STATE EXAMINATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT;

ACTIVITIES OF DAILY LIVING; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; CAREGIVERS; COGNITION DISORDERS; DISEASE PROGRESSION; EXCITATORY AMINO ACID ANTAGONISTS; FEMALE; FOLLOW-UP STUDIES; HOME NURSING; HUMANS; MALE; MENTAL STATUS SCHEDULE; PIPERIDINES; PSYCHOMETRICS; THIAZOLES; TIME AND MOTION STUDIES; TREATMENT OUTCOME;

EID: 16844383073     PISSN: 08930341     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.wad.0000157065.43282.bc     Document Type: Article

References (40)

1. Aisen PS, Davis KL, Berg JD, et al. A randomized controlled trial of prednisone in Alzheimer's disease. Alzheimer's Disease Cooperative Study. Neurology. 2000;54:588-593.
2. Aisen PS, Schafer KA, Grundman M, et al. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA. 2003;289:2819-2826.
3. Reines SA, Block GA, Morris JC, et al. Rofecoxib: no effect on Alzheimer's disease in a 1-year, randomized, blinded, controlled study. Neurology. 2004;62:66-71.
4. Sano M, Emesto C, Thomas RG, et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. N Engl J Med. 1997;336:1216-1222.
5. Thai LJ, Calvani M, Amato A, et al. A 1-year controlled trial of acetyl-1-carnitine in early-onset AD. Neurology. 2000;55:805-810.
6. Reisberg B. Functional assessment staging (FAST). Psychopharmacol Bull. 1988;24:653-659.
7. Birks J, Grimley Evans J, Iakovidou V, et al. Rivastigmine for Alzheimer's disease (Cochrane Review). The Cochrane Library, Issue 2. Oxford, UK: Update Software, 2002.
8. Birks JS, Melzer D, Beppu H. Donepezil for mild and moderate Alzheimer's disease (Cochrane Review). The Cochrane Library, Issue 2. Oxford, UK: Update Software, 2002.
9. Clegg A, Bryant J, Nicholson T, et al. Clinical and cost-effectiveness of donepezil, rivastigmine and galantamine for Alzheimer's Disease. London, UK: National Institute of Clinical Excellence, 2001.
10. Doody RS, Stevens JC, Beck C, et al. Practice parameter: management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2001;56:1154-1166.
11. Olin J, Schneider L. Galantamine for Alzheimer's disease (Cochrane Review). The Cochrane Library, Issue 4. Oxford, UK: Update Software, 2002.
12. Wilcock G, Howe I, Coles H, et al. A long-term comparison of galantamine and donepezil in the treatment of Alzheimer's disease. Drugs Aging. 2003;20:777-789.
13. Mohs RC, Doody RS, Morris JC, et al. A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology. 2001;57:481-488.
14. Van Gool WA, Weinstein HC, Schelters P, et al. Effect of hydroxychloroquine on progression of dementia in early Alzheimer's disease: an 18-month randomised, double-blind, placebo-controlled study. Lancet. 2001;358:455-460.
15. Winblad B, Engedal K, Soininen H, et al. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology. 2001;57:489-495.
16. Doody RS, Geldmacher DS, Gordon B, et al. Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease. Arch Neurol. 2001;58:427-433.
17. Farlow M, Anand R, Messina J Jr, et al. A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer's disease. Eur Neurol. 2000;44:236-241.
18. Raskind MA, Peskind ER, Wessel T, et al. Galantamine in AD: a 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group. Neurology. 2000;54:2261-2268.
19. Stern RG, Mohs RC, Davidson M, et al. A longitudinal study of Alzheimer's disease: measurement, rate, and predictors of cognitive deterioration. Am J Psychiatry. 1994;151:390-396.
20. Stern RG, Mohs RC, Bierer LM, et al. Deterioration on the Blessed test in Alzheimer's disease: longitudinal data and their implications for clinical trials and identification of subtypes. Psychiatry Res. 1992;42:101-110.
21. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189-198.
22. Clark CM, Sheppard L, Fillenbaum GG, et al. Variability in annual Mini-Mental State Examination score in patients with probable Alzheimer disease: a clinical perspective of data from the Consortium to Establish a Registry for Alzheimer's Disease. Arch Neurol. 1999;56:857-862.
23. Galasko D, Edland SD, Morris JC, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part XI. Clinical milestones in patients with Alzheimer's disease followed over 3 years. Neurology. 1995;45:1451-1455.
24. Feldman H, Sauter A, Donald A, et al. The disability assessment for dementia seal: a 12-month study of functional ability in mild to moderate severity Alzheimer disease. Alzheimer Dis Assoc Disord. 2001;15:89-95.
25. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34:939-944.
26. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry. 1984;141:1356-1364.
27. Gelinas I, Gauthier L, McIntyre M, et al. Development of a functional measure for persons with Alzheimer's disease: the disability assessment for dementia. Am J Occup Ther. 1999;53:471-481.
28. Feldman H, Gauthier S, Hecker J, et al. Efficacy of donepezil on maintenance of activities of daily living in patients with moderate to severe Alzheimer's disease and the effect on caregiver burden. J Am Geriatr Soc. 2003;51:737-744.
29. Sano M, Wilcock GK, Van Baelen B, et al. The effects of galantamine treatment on caregiver time in Alzheimer's disease. Int J Geriatr Psychiatry. 2003;18:942-950.
30. Galasko D, Bennett D, Sano M, et al. An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord. 1997;11(Suppl 2):S33-S39.
31. Reisberg B, Franssen E, Souren L, et al. Severity scales. In: Wimo A, Jonsson B, Karlsson G, Winblad B, eds. Health economics of dementia. Chichester: John Wiley and Sons, 1998:327-357.
32. Ungerson C. Policy is Personal. Sex, Gender and Informal Care. London, UK: Tavistock Publications, 1987.
33. Food and Drug Administration. Peripheral and central nervous system drugs advisory committee meeting. Rockville, MD: Department of Health and Human Services, Public Health Service, Food and Drug Administration, 1989.
34. Winblad B, Brodaty H, Gauthier S, et al. Pharmacotherapy of Alzheimer's disease: is there a need to redefine treatment success? Int J Geriatr Psychiatry. 2001;16:653-666.
35. Kavanagh S, Knapp M. Costs and cognitive disability: modelling the underlying associations. Br J Psychiatry. 2002;180:120-125.
36. Leontaridi R, Bell D. Health and Community Care Research Findings No. 8. Informal Care of the Elderly in Scotland and the UK. Edinburgh, UK: Scottish Executive Central Research Unit, 2001.
37. Machin D, McShane D. Providing Free Personal Care for Older People: Research Commissioned to Inform The Work of the Care Development Group. Edinburgh, UK: Scottish Executive Central Research Unit, 2001.
38. Rogers SL, Farlow MR, Doody RS, et al. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group. Neurology. 1998;50:136-145.
39. Albert SM, Sano M, Marder K, et al. Participation in clinical trials and long-term outcomes in Alzheimer's disease. Neurology. 1997;49:38-43.
40. Schneider LS, Olin JT, Lyness SA, et al. Eligibility of Alzheimer's disease clinic patients for clinical trials. J Am Geriatr Soc. 1997;45:923-928.